Влияние успешной психофармакотерапии расстройств тревожно-депрессивного спектра на выраженность хронической усталости у больных ревматоидным артритом
Влияние успешной психофармакотерапии расстройств тревожно-депрессивного спектра на выраженность хронической усталости у больных ревматоидным артритом
Абрамкин А.А., Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф., Ковалевская О.Б., Глухова С.И., Насонов Е.Л. Влияние успешной психофармакотерапии расстройств тревожно-депрессивного спектра на выраженность хронической усталости у больных ревматоидным артритом. Терапевтический архив. 2021; 93 (5): 551–560. DOI: 10.26442/00403660.2021.05.200786
DOI: 10.26442/00403660.2021.05.200786
________________________________________________
DOI: 10.26442/00403660.2021.05.200786
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Уточнить влияние успешной психофармакотерапии (ПФТ) расстройств тревожно-депрессивного спектра (РТДС) на выраженность хронической усталости у больных ревматоидным артритом (РА).
Материалы и методы. Обследованы 128 пациентов с достоверным диагнозом РА. Для оценки выраженности усталости использовали шкалу FSS (Fatigue Severity Scale), клинически выраженной усталость считалась при FSS≥4 баллов. РТДС диагностированы психиатром в ходе полуструктурированного интервью по критериям Международной классификации болезней 10-го пересмотра у 123 (96,1%) пациентов. Выраженность депрессии определяли по шкале депрессии Монтгомери–Асберг (MADRS), тревоги – по шкале тревоги Гамильтона (HAM-A). ПФТ предложена всем пациентам с РТДС, согласились на лечение – 52, отказался – 71. В зависимости от проводимой терапии выделены следующие терапевтические группы: 1-я – базисные противовоспалительные препараты – БПВП (n=39), 2-я – БПВП+ПФТ (n=43), 3-я – БПВП + генно-инженерные биологические препараты – ГИБП (n=32), 4-я: БПВП+ГИБП+ПФТ (n=9). Длительность терапии ГИБП варьировала от 1 года до 5 лет, длительность ПФТ – от 6 до 96 нед. Динамику РТДС и исходы РА через 5 лет оценивали у 83 (67,5%) больных. Предикторы хронической усталости через 5 лет наблюдения определяли с помощью многофакторной логистической регрессии.
Результаты. По результатам многофакторного логистического регрессионного анализа с клинически значимой усталостью через 5 лет после включения в исследование независимо положительно ассоциировалась только исходная клинически значимая усталость (отношение шансов 13,57; 95% доверительный интервал 3,044–60,486; p=0,01) и отрицательно – успешное лечение РТДС (отношение шансов 0,162; 95% доверительный интервал 0,032–0,809; p=0,027), R2=0,385, p<0,0001.
Заключение. Учитывая существенное влияние факторов, связанных с психическим здоровьем, на выраженность усталости, а также значимое положительное влияние ПФТ РТДС, всем больным РА с клинически значимой усталостью показана диагностика РТДС и в случае их выявления – назначение ПФТ.
Ключевые слова: ревматоидный артрит, расстройства тревожно-депрессивного спектра, хроническая усталость, предикторы, антидепрессанты
Materials and methods. 128 RA-patients were included. Severity of fatigue was measured with fatigue severity scale (FSS), clinically important fatigue was diagnosed in patients with FSS≥4. Anxiety and depressive disorders (ADD) were diagnosed by a licensed psychiatrist in 123 (96.1%) of RA-patients in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with Montgomery–Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-patients with ADD were divided into the following treatment groups: 1 – сDMARDs (n=39), 2 – сDMARDs+PPT (sertraline or mianserine), n=43, 3 – сDMARDs+bDMARDs (n=32), 4 – сDMARDs+bDMARDs+PPT (sertraline or mianserine), n=9. Biologics treatment duration varied from 1 to 5 years, antidepressants – from
6 to 96 weeks. 83 (67.5%) RA patients were assessed at five-years follow-up. Multinominal logistic regression analysis was conducted to determine factors associated with clinically important fatigue.
Results. Multinominal logistic regression analysis showed clinically important fatigue at baseline to be positively associated (OR 13.57; 95% CI 3.044–60.486; p=0.01) and remission of ADD – negatively associated (OR 0.162; 95% CI 0.032–0.809; p=0.027), with clinically important fatigue at 5 years follow-up (R2=0.385, p<0.0001).
Conclusion. Due to significant relationship between mental health status, antidepressants treatment and clinically important fatigue
in RA-patients, all patients reporting clinically important fatigue should be recommended mental health counselling by a licensed psychiatrist.
Keywords: rheumatoid arthritis, anxiety-depressive spectrum disorders, chronic fatigue, predictors, antidepressants
Материалы и методы. Обследованы 128 пациентов с достоверным диагнозом РА. Для оценки выраженности усталости использовали шкалу FSS (Fatigue Severity Scale), клинически выраженной усталость считалась при FSS≥4 баллов. РТДС диагностированы психиатром в ходе полуструктурированного интервью по критериям Международной классификации болезней 10-го пересмотра у 123 (96,1%) пациентов. Выраженность депрессии определяли по шкале депрессии Монтгомери–Асберг (MADRS), тревоги – по шкале тревоги Гамильтона (HAM-A). ПФТ предложена всем пациентам с РТДС, согласились на лечение – 52, отказался – 71. В зависимости от проводимой терапии выделены следующие терапевтические группы: 1-я – базисные противовоспалительные препараты – БПВП (n=39), 2-я – БПВП+ПФТ (n=43), 3-я – БПВП + генно-инженерные биологические препараты – ГИБП (n=32), 4-я: БПВП+ГИБП+ПФТ (n=9). Длительность терапии ГИБП варьировала от 1 года до 5 лет, длительность ПФТ – от 6 до 96 нед. Динамику РТДС и исходы РА через 5 лет оценивали у 83 (67,5%) больных. Предикторы хронической усталости через 5 лет наблюдения определяли с помощью многофакторной логистической регрессии.
Результаты. По результатам многофакторного логистического регрессионного анализа с клинически значимой усталостью через 5 лет после включения в исследование независимо положительно ассоциировалась только исходная клинически значимая усталость (отношение шансов 13,57; 95% доверительный интервал 3,044–60,486; p=0,01) и отрицательно – успешное лечение РТДС (отношение шансов 0,162; 95% доверительный интервал 0,032–0,809; p=0,027), R2=0,385, p<0,0001.
Заключение. Учитывая существенное влияние факторов, связанных с психическим здоровьем, на выраженность усталости, а также значимое положительное влияние ПФТ РТДС, всем больным РА с клинически значимой усталостью показана диагностика РТДС и в случае их выявления – назначение ПФТ.
Ключевые слова: ревматоидный артрит, расстройства тревожно-депрессивного спектра, хроническая усталость, предикторы, антидепрессанты
________________________________________________
Materials and methods. 128 RA-patients were included. Severity of fatigue was measured with fatigue severity scale (FSS), clinically important fatigue was diagnosed in patients with FSS≥4. Anxiety and depressive disorders (ADD) were diagnosed by a licensed psychiatrist in 123 (96.1%) of RA-patients in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with Montgomery–Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-patients with ADD were divided into the following treatment groups: 1 – сDMARDs (n=39), 2 – сDMARDs+PPT (sertraline or mianserine), n=43, 3 – сDMARDs+bDMARDs (n=32), 4 – сDMARDs+bDMARDs+PPT (sertraline or mianserine), n=9. Biologics treatment duration varied from 1 to 5 years, antidepressants – from
6 to 96 weeks. 83 (67.5%) RA patients were assessed at five-years follow-up. Multinominal logistic regression analysis was conducted to determine factors associated with clinically important fatigue.
Results. Multinominal logistic regression analysis showed clinically important fatigue at baseline to be positively associated (OR 13.57; 95% CI 3.044–60.486; p=0.01) and remission of ADD – negatively associated (OR 0.162; 95% CI 0.032–0.809; p=0.027), with clinically important fatigue at 5 years follow-up (R2=0.385, p<0.0001).
Conclusion. Due to significant relationship between mental health status, antidepressants treatment and clinically important fatigue
in RA-patients, all patients reporting clinically important fatigue should be recommended mental health counselling by a licensed psychiatrist.
Keywords: rheumatoid arthritis, anxiety-depressive spectrum disorders, chronic fatigue, predictors, antidepressants
Список литературы
1. Katz P. Fatigue in Rheumatoid Arthritis. Curr Rheumatol Rep. 2017;19(5):25. DOI:10.1007/s11926-017-0649-5
2. Hewlett S, Chalder T, Choy E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford). 2011;50(6):1004-6.
DOI:10.1093/rheumatology/keq282
3. Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35(2):409-15. DOI:10.1007/s10067-015-3035-6
4. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology. 2006;45(7):885-9. DOI:10.1093/rheumatology/kel021
5. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2015;54(6):964-71. DOI:10.1093/rheumatology/keu390
6. Gossec L, Steinberg G, Rouanet S, Combe B. Fatigue in rheumatoid arthritis: Quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS study. Clin Exp Rheumatol. 2015;33(5):664-70
7. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3. DOI:10.1001/archneur.1989.00520460115022
8. Ream E, Richardson A. Fatigue: A concept analysis. Int J Nurs Stud. 1996;33(5):519-29. DOI:10.1016/0020-7489(96)00004-1
9. Nordin Å, Taft C, Lundgren-Nilsson Å, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16(1):62.DOI:10.1186/s12874-016-0167-6
10. Meade T, Manolios N, Cumming SR, et al. Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2018;70(1):39-52. DOI:10.1002/acr.23243
11. Nikolaus S, Bode C, Taal E, van de Laar MAFJ. Fatigue and Factors Related to Fatigue in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2013;65(7):1128-46.DOI:10.1002/acr.21949
12. Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: A systematic review. Clin Psychol Rev. 2015;39:16-29. DOI:10.1016/j.cpr.2015.03.004
13. Van Dartel SAA, Repping-Wuts JWJ, Van Hoogmoed D, et al. Association between fatigue and pain in rheumatoid arthritis: Does pain precede fatigue or does fatigue precede pain? Arthritis Care Res. 2013;65(6):862-9. DOI:10.1002/acr.21932
14. Grøn KL, Ørnbjerg LM, Hetland ML, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programme. Clin Exp Rheumatol. 2014;32(6):869-77
15. Novaes GS, Perez MO, Beraldo MBB, et al. Correlation of fatigue with pain and disability in rheumatoid arthritis and osteoarthritis, respectively. Rev Bras Reumatol. 2011;51(5):447-55. DOI:10.1590/S0482-50042011000500005.
16. Rongen-van Dartel SAA, Repping-Wuts H, Donders R, et al. A multidimensional “path analysis” model of factors explaining fatigue in rheumatoid arthritis. Clin Exp Rheumatol. 34(2):200-6. DOI: 27049923
17. Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al.Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. DOI:10.2340/16501977-2090
18. Żołnierczyk-Zreda D, Jędryka-Góral A, Bugajska J, et al.The relationship between work, mental health, physical health, and fatigue in patients with rheumatoid arthritis: A cross-sectional study. J Health Psychol. 2020;25(5):665-73. DOI:10.1177/1359105317727842
19. Silva CFR, Duarte C, Ferreira RJO, et al. Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. Clin Exp Rheumatol. 2020;38(2):314-21.
20. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology. 2019;58(Suppl.5):29-34. DOI:10.1093/rheumatology/kez346
21. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford).2010;49(7):1294-302. DOI:10.1093/rheumatology/keq043
22. Olsen CL, Lie E, Kvien TK, Zangi HA. Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State. Arthritis Care Res. 2016;68(7):1043-8. DOI:10.1002/acr.22787
23. Druce KL, Jones GT, MacFarlane GJ, Basu N. Determining pathways to improvements in fatigue in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Arthritis Rheumatol. 2015;67(9):2303-10. DOI:10.1002/art.39238
24. Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2016;55(10):1786-90. DOI:10.1093/rheumatology/kew241
25. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: WHO; 1993.
26. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. DOI:10.1002/art.27584
27. Насонов ЕЛ. Ревматология. Российские Клинические Рекомендации. М.: ГЭОТАР-Медиа; 2017 [Nasonov EL. Rheumatology. Russian Clinical Guidelines. Moscow: GEOTAR-Media, 2017 (in Russian)].
28. Амирджанова В.Н., Койлубаева Г.Н., Горячев Д.В., и др. Валидация русско-язычной версии Health Assessment Questionnaire (HAQ). Научно-практическая ревматология. 2004;(2):59-64 [Amirdzhanova VN, Koilubaeva GN, Goriachev DV, et al. Validatsiia russko-iazychnoi versii Health Assessment Questionnaire (HAQ). Nauchno-prakticheskaia revmatologiia. 2004;(2):59-64 (in Russian)].
29. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR Response Criteria. Rheum Dis Clin North Am. 2009;35(4):745-57. DOI:10.1016/j.rdc.2009.10.001
30. van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. DOI: 10.1002/art.1780390105
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x
32. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. DOI: 10.1192/bjp.134.4.382
34. Лурия А.Р. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. 2-е изд. М.: МГУ, 1962 [Luria AR. Higher cortical functions of a person and their disorders in local brain lesions. 2nd ed. Moscow: MGU, 1962 (in Russian)].
35. Херсонский Б.Г. Метод пиктограмм в психодиагностике психических заболеваний. Киев: Здоровье, 1988 [Khersonskii BG. The method of pictograms in the psychodiagnostics of mental illness. Kiev: Health, 1988 (in Russian)].
36. Зейгарник Б.В. Патология Мышления. 2-е изд. М.: МГУ, 1962 [Zejgarnik BV. Pathology of Thinking. 2nd ed. Moscow: MGU, 1962 (in Russian)].
37. Альманах Психологических Тестов. 3-е изд. М.: КСП, 1995 [Almanac of Psychological Tests. 3rd ed. Moscow: KSP, 1995 (in Russian)]
38. Рубинштейн С.Я. Экспериментальные методики патопсихологии и опыт применения их в клинике. Ред. Бутенко Г. М.: Изд-во института психотерапии, 2010 [Rubinstein SYa. Experimental methods of pathopsychology and experience of their application in the clinic. Ed. Butenko G. Moscow: Publishing house of the Institute of Psychotherapy, 2010 (in Russian)].
39. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, 2000.
40. Герасимов АН. Медицинская статистика: учебное пособие. М.: Мед. информ. агентство, 2007 [Gerasimov AN. Medical Statistics: a tutorial. Moscow: Med. inform. agency, 2007 (in Russian)].
41. Choy EH. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatol (Oxford). 2019;58(Suppl. 5)V51-5. DOI:10.1093/rheumatology/kez389
42. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-analysis. Rheumatology. 2012;51(1):60-8. DOI:10.1093/rheumatology/ker162
43. Pae C-U, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10(10):1561-70. DOI:10.1517/14656560902988510
44. Üçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279-98. DOI:10.1002/art.24000
45. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009;301(2):198-209. DOI:10.1001/jama.2008.944
46. Madsen SG, Danneskiold-Samsøe B, Stockmarr A, Bartels E. Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol. 2016;45(4):255-61. DOI:10.3109/03009742.2015.1095943
47. Van Steenbergen HW, Tsonaka R, Huizinga TWJ, et al. Fatigue in rheumatoid arthritis; A persistent problem: A large longitudinal study. RMD Open. 2015;1(1):e000041. DOI:10.1136/rmdopen-2014-000041
48. Nicassio PM, Ormseth SR, Custodio MK, et al. A multidimensional model of fatigue in patients with rheumatoid arthritis. J Rheumatol. 2012;39(9):1807-13. DOI:10.3899/jrheum.111068
49. Szady P, Bączyk G, Kozłowska K. Fatigue and sleep quality in rheumatoid arthritis patients during hospital admission. Reumatologia. 2017;55(2):65-72. DOI:10.5114/reum.2017.67600
50. Albayrak Gİ, Balkarli A, Can B, et al. Pain, depression levels, fatigue, sleep quality, and quality of life inelderly patients with rheumatoid arthritis. Turkish J Med Sci. 2017;47(3):847-53.DOI:10.3906/sag-1603-147
51. Лисицына Т.А., Вельтищев Д.Ю., Герасимов А.Н., и др. Выраженность усталости и ее связь с депрессией, болью и воспалительной активностью при ревматоидном артрите. Терапевтический архив. 2013;85(5):8-15 [Lisitsyna TA, Veltishchev DY, Gerasimov AN, et al. The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(5):8-15 (in Russian)].
2. Hewlett S, Chalder T, Choy E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford). 2011;50(6):1004-6.
DOI:10.1093/rheumatology/keq282
3. Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35(2):409-15. DOI:10.1007/s10067-015-3035-6
4. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology. 2006;45(7):885-9. DOI:10.1093/rheumatology/kel021
5. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2015;54(6):964-71. DOI:10.1093/rheumatology/keu390
6. Gossec L, Steinberg G, Rouanet S, Combe B. Fatigue in rheumatoid arthritis: Quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS study. Clin Exp Rheumatol. 2015;33(5):664-70
7. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3. DOI:10.1001/archneur.1989.00520460115022
8. Ream E, Richardson A. Fatigue: A concept analysis. Int J Nurs Stud. 1996;33(5):519-29. DOI:10.1016/0020-7489(96)00004-1
9. Nordin Å, Taft C, Lundgren-Nilsson Å, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16(1):62.DOI:10.1186/s12874-016-0167-6
10. Meade T, Manolios N, Cumming SR, et al. Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2018;70(1):39-52. DOI:10.1002/acr.23243
11. Nikolaus S, Bode C, Taal E, van de Laar MAFJ. Fatigue and Factors Related to Fatigue in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2013;65(7):1128-46.DOI:10.1002/acr.21949
12. Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: A systematic review. Clin Psychol Rev. 2015;39:16-29. DOI:10.1016/j.cpr.2015.03.004
13. Van Dartel SAA, Repping-Wuts JWJ, Van Hoogmoed D, et al. Association between fatigue and pain in rheumatoid arthritis: Does pain precede fatigue or does fatigue precede pain? Arthritis Care Res. 2013;65(6):862-9. DOI:10.1002/acr.21932
14. Grøn KL, Ørnbjerg LM, Hetland ML, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programme. Clin Exp Rheumatol. 2014;32(6):869-77
15. Novaes GS, Perez MO, Beraldo MBB, et al. Correlation of fatigue with pain and disability in rheumatoid arthritis and osteoarthritis, respectively. Rev Bras Reumatol. 2011;51(5):447-55. DOI:10.1590/S0482-50042011000500005.
16. Rongen-van Dartel SAA, Repping-Wuts H, Donders R, et al. A multidimensional “path analysis” model of factors explaining fatigue in rheumatoid arthritis. Clin Exp Rheumatol. 34(2):200-6. DOI: 27049923
17. Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al.Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. DOI:10.2340/16501977-2090
18. Żołnierczyk-Zreda D, Jędryka-Góral A, Bugajska J, et al.The relationship between work, mental health, physical health, and fatigue in patients with rheumatoid arthritis: A cross-sectional study. J Health Psychol. 2020;25(5):665-73. DOI:10.1177/1359105317727842
19. Silva CFR, Duarte C, Ferreira RJO, et al. Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. Clin Exp Rheumatol. 2020;38(2):314-21.
20. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology. 2019;58(Suppl.5):29-34. DOI:10.1093/rheumatology/kez346
21. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford).2010;49(7):1294-302. DOI:10.1093/rheumatology/keq043
22. Olsen CL, Lie E, Kvien TK, Zangi HA. Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State. Arthritis Care Res. 2016;68(7):1043-8. DOI:10.1002/acr.22787
23. Druce KL, Jones GT, MacFarlane GJ, Basu N. Determining pathways to improvements in fatigue in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Arthritis Rheumatol. 2015;67(9):2303-10. DOI:10.1002/art.39238
24. Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2016;55(10):1786-90. DOI:10.1093/rheumatology/kew241
25. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: WHO; 1993.
26. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. DOI:10.1002/art.27584
27. Nasonov EL. Rheumatology. Russian Clinical Guidelines. Moscow: GEOTAR-Media, 2017 (in Russian).
28. Amirdzhanova VN, Koilubaeva GN, Goriachev DV, et al. Validatsiia russko-iazychnoi versii Health Assessment Questionnaire (HAQ). Nauchno-prakticheskaia revmatologiia. 2004;(2):59-64 (in Russian)
29. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR Response Criteria. Rheum Dis Clin North Am. 2009;35(4):745-57. DOI:10.1016/j.rdc.2009.10.001
30. van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. DOI: 10.1002/art.1780390105
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x
32. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. DOI: 10.1192/bjp.134.4.382
34. Luria AR. Higher cortical functions of a person and their disorders in local brain lesions. 2nd ed. Moscow: MGU, 1962 (in Russian)
35. Khersonskii BG. The method of pictograms in the psychodiagnostics of mental illness. Kiev: Health, 1988 (in Russian)
36. Zejgarnik BV. Pathology of Thinking. 2nd ed. Moscow: MGU, 1962 (in Russian)
37. Almanac of Psychological Tests. 3rd ed. Moscow: KSP, 1995 (in Russian)
38. Rubinstein SYa. Experimental methods of pathopsychology and experience of their application in the clinic. Ed. Butenko G. Moscow: Publishing house of the Institute of Psychotherapy, 2010 (in Russian)
39. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, 2000.
40. Gerasimov AN. Medical Statistics: a tutorial. Moscow: Med. inform. agency, 2007 (in Russian)
41. Choy EH. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatol (Oxford). 2019;58(Suppl. 5)V51-5. DOI:10.1093/rheumatology/kez389
42. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-analysis. Rheumatology. 2012;51(1):60-8. DOI:10.1093/rheumatology/ker162
43. Pae C-U, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10(10):1561-70. DOI:10.1517/14656560902988510
44. Üçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279-98. DOI:10.1002/art.24000
45. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009;301(2):198-209. DOI:10.1001/jama.2008.944
46. Madsen SG, Danneskiold-Samsøe B, Stockmarr A, Bartels E. Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol. 2016;45(4):255-61. DOI:10.3109/03009742.2015.1095943
47. Van Steenbergen HW, Tsonaka R, Huizinga TWJ, et al. Fatigue in rheumatoid arthritis; A persistent problem: A large longitudinal study. RMD Open. 2015;1(1):e000041. DOI:10.1136/rmdopen-2014-000041
48. Nicassio PM, Ormseth SR, Custodio MK, et al. A multidimensional model of fatigue in patients with rheumatoid arthritis. J Rheumatol. 2012;39(9):1807-13. DOI:10.3899/jrheum.111068
49. Szady P, Bączyk G, Kozłowska K. Fatigue and sleep quality in rheumatoid arthritis patients during hospital admission. Reumatologia. 2017;55(2):65-72. DOI:10.5114/reum.2017.67600
50. Albayrak Gİ, Balkarli A, Can B, et al. Pain, depression levels, fatigue, sleep quality, and quality of life inelderly patients with rheumatoid arthritis. Turkish J Med Sci. 2017;47(3):847-53.DOI:10.3906/sag-1603-147
51. Lisitsyna TA, Veltishchev DY, Gerasimov AN, et al. The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(5):8-15 (in Russian)
2. Hewlett S, Chalder T, Choy E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford). 2011;50(6):1004-6.
DOI:10.1093/rheumatology/keq282
3. Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35(2):409-15. DOI:10.1007/s10067-015-3035-6
4. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology. 2006;45(7):885-9. DOI:10.1093/rheumatology/kel021
5. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2015;54(6):964-71. DOI:10.1093/rheumatology/keu390
6. Gossec L, Steinberg G, Rouanet S, Combe B. Fatigue in rheumatoid arthritis: Quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS study. Clin Exp Rheumatol. 2015;33(5):664-70
7. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3. DOI:10.1001/archneur.1989.00520460115022
8. Ream E, Richardson A. Fatigue: A concept analysis. Int J Nurs Stud. 1996;33(5):519-29. DOI:10.1016/0020-7489(96)00004-1
9. Nordin Å, Taft C, Lundgren-Nilsson Å, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16(1):62.DOI:10.1186/s12874-016-0167-6
10. Meade T, Manolios N, Cumming SR, et al. Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2018;70(1):39-52. DOI:10.1002/acr.23243
11. Nikolaus S, Bode C, Taal E, van de Laar MAFJ. Fatigue and Factors Related to Fatigue in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2013;65(7):1128-46.DOI:10.1002/acr.21949
12. Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: A systematic review. Clin Psychol Rev. 2015;39:16-29. DOI:10.1016/j.cpr.2015.03.004
13. Van Dartel SAA, Repping-Wuts JWJ, Van Hoogmoed D, et al. Association between fatigue and pain in rheumatoid arthritis: Does pain precede fatigue or does fatigue precede pain? Arthritis Care Res. 2013;65(6):862-9. DOI:10.1002/acr.21932
14. Grøn KL, Ørnbjerg LM, Hetland ML, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programme. Clin Exp Rheumatol. 2014;32(6):869-77
15. Novaes GS, Perez MO, Beraldo MBB, et al. Correlation of fatigue with pain and disability in rheumatoid arthritis and osteoarthritis, respectively. Rev Bras Reumatol. 2011;51(5):447-55. DOI:10.1590/S0482-50042011000500005.
16. Rongen-van Dartel SAA, Repping-Wuts H, Donders R, et al. A multidimensional “path analysis” model of factors explaining fatigue in rheumatoid arthritis. Clin Exp Rheumatol. 34(2):200-6. DOI: 27049923
17. Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al.Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. DOI:10.2340/16501977-2090
18. Żołnierczyk-Zreda D, Jędryka-Góral A, Bugajska J, et al.The relationship between work, mental health, physical health, and fatigue in patients with rheumatoid arthritis: A cross-sectional study. J Health Psychol. 2020;25(5):665-73. DOI:10.1177/1359105317727842
19. Silva CFR, Duarte C, Ferreira RJO, et al. Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. Clin Exp Rheumatol. 2020;38(2):314-21.
20. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology. 2019;58(Suppl.5):29-34. DOI:10.1093/rheumatology/kez346
21. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford).2010;49(7):1294-302. DOI:10.1093/rheumatology/keq043
22. Olsen CL, Lie E, Kvien TK, Zangi HA. Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State. Arthritis Care Res. 2016;68(7):1043-8. DOI:10.1002/acr.22787
23. Druce KL, Jones GT, MacFarlane GJ, Basu N. Determining pathways to improvements in fatigue in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Arthritis Rheumatol. 2015;67(9):2303-10. DOI:10.1002/art.39238
24. Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2016;55(10):1786-90. DOI:10.1093/rheumatology/kew241
25. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: WHO; 1993.
26. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. DOI:10.1002/art.27584
27. Насонов ЕЛ. Ревматология. Российские Клинические Рекомендации. М.: ГЭОТАР-Медиа; 2017 [Nasonov EL. Rheumatology. Russian Clinical Guidelines. Moscow: GEOTAR-Media, 2017 (in Russian)].
28. Амирджанова В.Н., Койлубаева Г.Н., Горячев Д.В., и др. Валидация русско-язычной версии Health Assessment Questionnaire (HAQ). Научно-практическая ревматология. 2004;(2):59-64 [Amirdzhanova VN, Koilubaeva GN, Goriachev DV, et al. Validatsiia russko-iazychnoi versii Health Assessment Questionnaire (HAQ). Nauchno-prakticheskaia revmatologiia. 2004;(2):59-64 (in Russian)].
29. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR Response Criteria. Rheum Dis Clin North Am. 2009;35(4):745-57. DOI:10.1016/j.rdc.2009.10.001
30. van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. DOI: 10.1002/art.1780390105
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x
32. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. DOI: 10.1192/bjp.134.4.382
34. Лурия А.Р. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. 2-е изд. М.: МГУ, 1962 [Luria AR. Higher cortical functions of a person and their disorders in local brain lesions. 2nd ed. Moscow: MGU, 1962 (in Russian)].
35. Херсонский Б.Г. Метод пиктограмм в психодиагностике психических заболеваний. Киев: Здоровье, 1988 [Khersonskii BG. The method of pictograms in the psychodiagnostics of mental illness. Kiev: Health, 1988 (in Russian)].
36. Зейгарник Б.В. Патология Мышления. 2-е изд. М.: МГУ, 1962 [Zejgarnik BV. Pathology of Thinking. 2nd ed. Moscow: MGU, 1962 (in Russian)].
37. Альманах Психологических Тестов. 3-е изд. М.: КСП, 1995 [Almanac of Psychological Tests. 3rd ed. Moscow: KSP, 1995 (in Russian)]
38. Рубинштейн С.Я. Экспериментальные методики патопсихологии и опыт применения их в клинике. Ред. Бутенко Г. М.: Изд-во института психотерапии, 2010 [Rubinstein SYa. Experimental methods of pathopsychology and experience of their application in the clinic. Ed. Butenko G. Moscow: Publishing house of the Institute of Psychotherapy, 2010 (in Russian)].
39. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, 2000.
40. Герасимов АН. Медицинская статистика: учебное пособие. М.: Мед. информ. агентство, 2007 [Gerasimov AN. Medical Statistics: a tutorial. Moscow: Med. inform. agency, 2007 (in Russian)].
41. Choy EH. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatol (Oxford). 2019;58(Suppl. 5)V51-5. DOI:10.1093/rheumatology/kez389
42. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-analysis. Rheumatology. 2012;51(1):60-8. DOI:10.1093/rheumatology/ker162
43. Pae C-U, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10(10):1561-70. DOI:10.1517/14656560902988510
44. Üçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279-98. DOI:10.1002/art.24000
45. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009;301(2):198-209. DOI:10.1001/jama.2008.944
46. Madsen SG, Danneskiold-Samsøe B, Stockmarr A, Bartels E. Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol. 2016;45(4):255-61. DOI:10.3109/03009742.2015.1095943
47. Van Steenbergen HW, Tsonaka R, Huizinga TWJ, et al. Fatigue in rheumatoid arthritis; A persistent problem: A large longitudinal study. RMD Open. 2015;1(1):e000041. DOI:10.1136/rmdopen-2014-000041
48. Nicassio PM, Ormseth SR, Custodio MK, et al. A multidimensional model of fatigue in patients with rheumatoid arthritis. J Rheumatol. 2012;39(9):1807-13. DOI:10.3899/jrheum.111068
49. Szady P, Bączyk G, Kozłowska K. Fatigue and sleep quality in rheumatoid arthritis patients during hospital admission. Reumatologia. 2017;55(2):65-72. DOI:10.5114/reum.2017.67600
50. Albayrak Gİ, Balkarli A, Can B, et al. Pain, depression levels, fatigue, sleep quality, and quality of life inelderly patients with rheumatoid arthritis. Turkish J Med Sci. 2017;47(3):847-53.DOI:10.3906/sag-1603-147
51. Лисицына Т.А., Вельтищев Д.Ю., Герасимов А.Н., и др. Выраженность усталости и ее связь с депрессией, болью и воспалительной активностью при ревматоидном артрите. Терапевтический архив. 2013;85(5):8-15 [Lisitsyna TA, Veltishchev DY, Gerasimov AN, et al. The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(5):8-15 (in Russian)].
________________________________________________
2. Hewlett S, Chalder T, Choy E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford). 2011;50(6):1004-6.
DOI:10.1093/rheumatology/keq282
3. Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35(2):409-15. DOI:10.1007/s10067-015-3035-6
4. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology. 2006;45(7):885-9. DOI:10.1093/rheumatology/kel021
5. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2015;54(6):964-71. DOI:10.1093/rheumatology/keu390
6. Gossec L, Steinberg G, Rouanet S, Combe B. Fatigue in rheumatoid arthritis: Quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS study. Clin Exp Rheumatol. 2015;33(5):664-70
7. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3. DOI:10.1001/archneur.1989.00520460115022
8. Ream E, Richardson A. Fatigue: A concept analysis. Int J Nurs Stud. 1996;33(5):519-29. DOI:10.1016/0020-7489(96)00004-1
9. Nordin Å, Taft C, Lundgren-Nilsson Å, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16(1):62.DOI:10.1186/s12874-016-0167-6
10. Meade T, Manolios N, Cumming SR, et al. Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2018;70(1):39-52. DOI:10.1002/acr.23243
11. Nikolaus S, Bode C, Taal E, van de Laar MAFJ. Fatigue and Factors Related to Fatigue in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2013;65(7):1128-46.DOI:10.1002/acr.21949
12. Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: A systematic review. Clin Psychol Rev. 2015;39:16-29. DOI:10.1016/j.cpr.2015.03.004
13. Van Dartel SAA, Repping-Wuts JWJ, Van Hoogmoed D, et al. Association between fatigue and pain in rheumatoid arthritis: Does pain precede fatigue or does fatigue precede pain? Arthritis Care Res. 2013;65(6):862-9. DOI:10.1002/acr.21932
14. Grøn KL, Ørnbjerg LM, Hetland ML, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programme. Clin Exp Rheumatol. 2014;32(6):869-77
15. Novaes GS, Perez MO, Beraldo MBB, et al. Correlation of fatigue with pain and disability in rheumatoid arthritis and osteoarthritis, respectively. Rev Bras Reumatol. 2011;51(5):447-55. DOI:10.1590/S0482-50042011000500005.
16. Rongen-van Dartel SAA, Repping-Wuts H, Donders R, et al. A multidimensional “path analysis” model of factors explaining fatigue in rheumatoid arthritis. Clin Exp Rheumatol. 34(2):200-6. DOI: 27049923
17. Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al.Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. DOI:10.2340/16501977-2090
18. Żołnierczyk-Zreda D, Jędryka-Góral A, Bugajska J, et al.The relationship between work, mental health, physical health, and fatigue in patients with rheumatoid arthritis: A cross-sectional study. J Health Psychol. 2020;25(5):665-73. DOI:10.1177/1359105317727842
19. Silva CFR, Duarte C, Ferreira RJO, et al. Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. Clin Exp Rheumatol. 2020;38(2):314-21.
20. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology. 2019;58(Suppl.5):29-34. DOI:10.1093/rheumatology/kez346
21. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford).2010;49(7):1294-302. DOI:10.1093/rheumatology/keq043
22. Olsen CL, Lie E, Kvien TK, Zangi HA. Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State. Arthritis Care Res. 2016;68(7):1043-8. DOI:10.1002/acr.22787
23. Druce KL, Jones GT, MacFarlane GJ, Basu N. Determining pathways to improvements in fatigue in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Arthritis Rheumatol. 2015;67(9):2303-10. DOI:10.1002/art.39238
24. Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatol (Oxford). 2016;55(10):1786-90. DOI:10.1093/rheumatology/kew241
25. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: WHO; 1993.
26. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. DOI:10.1002/art.27584
27. Nasonov EL. Rheumatology. Russian Clinical Guidelines. Moscow: GEOTAR-Media, 2017 (in Russian).
28. Amirdzhanova VN, Koilubaeva GN, Goriachev DV, et al. Validatsiia russko-iazychnoi versii Health Assessment Questionnaire (HAQ). Nauchno-prakticheskaia revmatologiia. 2004;(2):59-64 (in Russian)
29. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR Response Criteria. Rheum Dis Clin North Am. 2009;35(4):745-57. DOI:10.1016/j.rdc.2009.10.001
30. van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. DOI: 10.1002/art.1780390105
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x
32. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. DOI: 10.1192/bjp.134.4.382
34. Luria AR. Higher cortical functions of a person and their disorders in local brain lesions. 2nd ed. Moscow: MGU, 1962 (in Russian)
35. Khersonskii BG. The method of pictograms in the psychodiagnostics of mental illness. Kiev: Health, 1988 (in Russian)
36. Zejgarnik BV. Pathology of Thinking. 2nd ed. Moscow: MGU, 1962 (in Russian)
37. Almanac of Psychological Tests. 3rd ed. Moscow: KSP, 1995 (in Russian)
38. Rubinstein SYa. Experimental methods of pathopsychology and experience of their application in the clinic. Ed. Butenko G. Moscow: Publishing house of the Institute of Psychotherapy, 2010 (in Russian)
39. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, 2000.
40. Gerasimov AN. Medical Statistics: a tutorial. Moscow: Med. inform. agency, 2007 (in Russian)
41. Choy EH. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatol (Oxford). 2019;58(Suppl. 5)V51-5. DOI:10.1093/rheumatology/kez389
42. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-analysis. Rheumatology. 2012;51(1):60-8. DOI:10.1093/rheumatology/ker162
43. Pae C-U, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10(10):1561-70. DOI:10.1517/14656560902988510
44. Üçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279-98. DOI:10.1002/art.24000
45. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009;301(2):198-209. DOI:10.1001/jama.2008.944
46. Madsen SG, Danneskiold-Samsøe B, Stockmarr A, Bartels E. Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol. 2016;45(4):255-61. DOI:10.3109/03009742.2015.1095943
47. Van Steenbergen HW, Tsonaka R, Huizinga TWJ, et al. Fatigue in rheumatoid arthritis; A persistent problem: A large longitudinal study. RMD Open. 2015;1(1):e000041. DOI:10.1136/rmdopen-2014-000041
48. Nicassio PM, Ormseth SR, Custodio MK, et al. A multidimensional model of fatigue in patients with rheumatoid arthritis. J Rheumatol. 2012;39(9):1807-13. DOI:10.3899/jrheum.111068
49. Szady P, Bączyk G, Kozłowska K. Fatigue and sleep quality in rheumatoid arthritis patients during hospital admission. Reumatologia. 2017;55(2):65-72. DOI:10.5114/reum.2017.67600
50. Albayrak Gİ, Balkarli A, Can B, et al. Pain, depression levels, fatigue, sleep quality, and quality of life inelderly patients with rheumatoid arthritis. Turkish J Med Sci. 2017;47(3):847-53.DOI:10.3906/sag-1603-147
51. Lisitsyna TA, Veltishchev DY, Gerasimov AN, et al. The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(5):8-15 (in Russian)
Авторы
А.А. Абрамкин*1, Т.А. Лисицына1, Д.Ю. Вельтищев2,3, О.Ф. Серавина2, О.Б. Ковалевская2, С.И. Глухова1, Е.Л. Насонов1,4
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 Московский научно-исследовательский институт психиатрии – филиал ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России, Москва, Россия;
3 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
4 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*79096237832@ya.ru
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Moscow Research Institute of Psychiatry – branch of the Serbsky National Medical Research Center of Psychiatry and Narcology, Moscow, Russia;
3 Pirogov Russian National Research Medical University, Moscow, Russia;
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*79096237832@ya.ru
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 Московский научно-исследовательский институт психиатрии – филиал ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России, Москва, Россия;
3 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
4 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*79096237832@ya.ru
________________________________________________
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Moscow Research Institute of Psychiatry – branch of the Serbsky National Medical Research Center of Psychiatry and Narcology, Moscow, Russia;
3 Pirogov Russian National Research Medical University, Moscow, Russia;
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*79096237832@ya.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.